



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas
Baile Átha Cliath 11, D11 XKF3
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas,
Dublin 11, D11 XKF3
Tel: (01) 864 7100 Fax: (01) 834 3589

Michael Cahill, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

7th October 2025

PQ: 50356/25

To ask the Minister for Health if funding for automatic wearable blood sugar sensors can be provided for those Type 2-rated patients whose condition makes them prone to regular, dangerous Hypoglycaemia or Hyperglycaemia blood sugar levels, and who are presently drawing multiple small blood samples on a daily basis, manually from their finger pads; and if she will make a statement on the matter. -Michael Cahill

Dear Deputy Cahill,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 50356/25), which you submitted to the Minister for Health for response.

The Health Information and Quality Authority (HIQA) Rapid Health Technology Assessment (HTA) of Continuous Glucose Monitoring (CGM) in Adults with Type 1 Diabetes Mellitus was published on 29th September 2023. The published document can be found at: [Rapid Health Technology Assessment of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Mellitus | HIQA](#).

In line with the advice from HIQA and due to the budget impact associated with CGM sensors, the HSE established a single national reimbursement application system for all CGM sensors on the reimbursement list on 01/12/2023.

Reimbursement support for CGM sensors at this point in time is based on the HIQA HTA and is for patients with type 1 diabetes mellitus regardless of age, who have required insulin from the outset. Reimbursement does not extend to other cohorts such as people with type 2 diabetes who require insulin, or patients previously diagnosed with type 2 diabetes which is now classified as type 1 diabetes based on laboratory investigations such as C-peptide measurement or diabetes-specific autoantibodies. To date, a HTA of CGM sensors for people with type 2 diabetes mellitus or other types of diabetes excluded from the HTA referenced above, such as latent autoimmune diabetes in adults (LADA), type 3c diabetes,

monogenic forms of diabetes etc. has not been undertaken. Therefore, there is limited information to support the extension of reimbursement to this cohort, including cost-effectiveness assessment and budget impact of same.

An application for reimbursement support of CGM sensors can be submitted for any patient, and each application is reviewed centrally by the HSE-Medicines Management Programme (MMP) on a case-by-case basis.

To date a health technology assessment of CGM sensors for people with type 2 diabetes mellitus has not been undertaken. Therefore, there is limited information to support the extension of reimbursement to this cohort, including cost-effectiveness and budget impact of same.

Yours sincerely,

Suzanne Doyle
Primary Care Reimbursement Service

The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: Oireachtas.pcrs@hse.ie